Novo Nordisk Rebrands as Novo and Partners with Anthropic to Accelerate Drug Discovery in Diabetes and Obesity
Novo Nordisk, now rebranded as 'Novo,' is focusing on strengthening its position in the diabetes and obesity drug markets. The company aims to become leaner and more competitive under CEO Mike Doustdar while accelerating drug discovery through a partnership with Anthropic. This collaboration will leverage advanced AI models like Claude Science for R&D and software engineering, potentially speeding up clinical trials. Despite these efforts, Novo is projecting sales declines in 2026 and not expecting to return quickly to the high growth rates seen previously. The company has a robust pipeline with multiple drugs across various phases of development targeting obesity, diabetes, rare blood disorders, and endocrine diseases. For H1 FY26, it reported DKK175.3 billion in net sales (up 13% YoY) and an operating profit of DKK86.7 billion (up 20%). The global market for diabetes and obesity treatments is vast but underpenetrated—only about 9% of diabetes prescriptions are GLP-1 based, while just 1% of obese individuals receive branded anti-obesity medicine. Novo's long-term growth strategy hinges on expanding treatment access and accelerating its R&D pipeline.
Tickers: $NVO